Last reviewed 2026-05-22 · How we verify

Valsartan Capsules

Valsartan Capsules is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Affiliated Hospital of Nantong University. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction. Also known as: Valsartan Capsules，National Medicine Permission Number H20040217，86900100000095.

Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.

Valsartan Capsules are a small molecule that acts as a Type-1 angiotensin II receptor antagonist. They are used to treat conditions such as hypertension, diabetes-related complications, and heart failure, as well as to evaluate arterial stiffness in elderly patients with hypertension.

At a glance

Mechanism of action

Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in reduced blood pressure and improved cardiac function.

Approved indications

• Hypertension
• Heart failure with reduced ejection fraction
• Post-myocardial infarction left ventricular dysfunction

Common side effects

• Dizziness
• Fatigue
• Hyperkalemia
• Cough
• Headache
• Hypotension

Key clinical trials

• A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
• FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan (PHASE3)
• Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
• Heart Failure Polypill at a Safety Net Hospital (PHASE2)
• PDD in Type 2 Diabetes w/wo Diastolic Dysfunction (PHASE2)
• Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF (PHASE3)
• Repurposing Valsartan May Protect Against Pulmonary Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Valsartan Capsules CI brief — competitive landscape report
• Valsartan Capsules updates RSS · CI watch RSS
• Affiliated Hospital of Nantong University portfolio CI

Frequently asked questions about Valsartan Capsules

Related

• Drug class: All Angiotensin II receptor blocker (ARB) drugs
• Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
• Manufacturer: Affiliated Hospital of Nantong University — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Hypertension
• Indication: Drugs for Heart failure with reduced ejection fraction
• Indication: Drugs for Post-myocardial infarction left ventricular dysfunction
• Also known as: Valsartan Capsules，National Medicine Permission Number H20040217，86900100000095

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing